Abstract
Respiratory syncytial virus infections recur throughout life despite induction of immunity by the first natural infection. Results of an extensive series of studies indicate that the virus adversely affects the human antiviral recall response to challenge, although subsequent infections are less severe than the initial illness. The observations suggest that candidate vaccines for respiratory syncytial virus should not be expected to prevent clinical illness upon subsequent exposure. Candidate vaccines may be considered effective if they render a subsequent natural infection less severe. This is what would be expected from an initial and commonly more severe natural infection and sensitization.
Keywords:
Anamnestic immune response; Influenza virus; Lymphocytes; Peripheral blood mononuclear cells; Respiratory syncytial virus; Vaccine evaluation.
Copyright © 2019 Elsevier Ltd. All rights reserved.
MeSH terms
-
Animals
-
Cytokines / biosynthesis
-
Cytokines / immunology
-
Host-Pathogen Interactions / immunology*
-
Humans
-
Immunity, Innate / drug effects*
-
Immunogenicity, Vaccine
-
Immunologic Memory / drug effects*
-
Influenza A virus / immunology
-
Influenza A virus / pathogenicity
-
Influenza, Human / immunology
-
Influenza, Human / pathology
-
Influenza, Human / virology
-
Leukocytes, Mononuclear / drug effects
-
Leukocytes, Mononuclear / immunology
-
Leukocytes, Mononuclear / virology
-
Lung / drug effects
-
Lung / immunology
-
Lung / virology
-
Respiratory Syncytial Virus Infections / immunology
-
Respiratory Syncytial Virus Infections / pathology
-
Respiratory Syncytial Virus Infections / prevention & control*
-
Respiratory Syncytial Virus Infections / virology
-
Respiratory Syncytial Virus Vaccines / administration & dosage*
-
Respiratory Syncytial Virus Vaccines / biosynthesis
-
Respiratory Syncytial Virus, Human / immunology*
-
Respiratory Syncytial Virus, Human / pathogenicity
-
Severity of Illness Index
Substances
-
Cytokines
-
Respiratory Syncytial Virus Vaccines